Platelet Rich Plasma for Knee Arthritis

(PRP-PEPC Trial)

This trial examines how two different machines prepare Platelet Rich Plasma (PRP) for treating knee osteoarthritis, a condition where knee cartilage wears down. Researchers aim to determine if PRP from these machines affects symptoms differently. Participants will receive PRP injections prepared by either the APEX Biologix XCELL PRP System or the Emcyte PurePRP Supraphysiologic Concentrating System. This trial may suit individuals who have experienced knee osteoarthritis symptoms for at least three months and can participate in physical therapy. As a Phase 4 trial, it involves an FDA-approved treatment, seeking to understand its benefits for more patients.

The trial does not specify if you need to stop taking your current medications. However, if you are taking chemotherapy, regular prednisone, or regular anti-inflammatory medications, you may not be eligible to participate.

Research has shown that Platelet Rich Plasma (PRP) treatments are generally well-tolerated. The FDA has approved the APEX Biologix XCELL PRP System and the Emcyte PurePRP Supraphysiologic Concentrating System for preparing PRP, indicating their safety.

Previous studies found that PRP injections can relieve pain from knee osteoarthritis, where the knee joint cartilage wears down. Many patients experience pain relief for 6 to 12 months after treatment. Side effects are usually mild and may include temporary pain or swelling at the injection site.

Researchers are excited about using Platelet Rich Plasma (PRP) for knee arthritis because it offers a regenerative approach to treatment. Unlike standard options like pain relievers and physical therapy, PRP uses components derived from the patient's own blood to potentially stimulate healing in the knee joint. The APEX Biologix XCELL PRP System and Emcyte PurePRP Supraphysiologic Concentrating System both produce PRP with high concentrations of platelets, which may enhance the body's natural repair processes. This innovative method has the potential to not only alleviate pain but also improve joint function, offering a promising alternative to conventional management methods for knee arthritis.

This trial compares two methods of delivering platelet-rich plasma (PRP) for knee osteoarthritis: the APEX Biologix XCELL PRP System and the Emcyte PurePRP Supraphysiologic Concentrating System. Studies have shown that PRP injections can alleviate knee osteoarthritis. Patients using either system often experience pain relief for 6 to 12 months post-treatment. Research suggests a 60% to 70% chance that PRP will effectively reduce knee pain and enhance movement. Additionally, PRP has proven to be as effective, or even superior, to other common treatments like hyaluronic acid injections. Both systems have FDA approval, ensuring they meet safety standards for use.¹²⁴⁵⁶